This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Giotrif
  • /
  • LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 29...
Clinical trial

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Read time: 1 mins
Last updated:1st Mar 2012

This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy. The primary objective of this trial is to compare the efficacy of BIBW 2992 to erlotinib as second-line treatment in this group of patients.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy
Enrollment: 795
Study Start Date: March 2012
Estimated Study Completion Date: November 2015
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Afatinib
- Active Comparator: Erlotinib


Related journal: Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Category Value
Study start date 2012-03-01

View full details